Stay updated on Resmetirom in NASH and Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.

Latest updates to the Resmetirom in NASH and Fibrosis Clinical Trial page
- ChecktodayChange DetectedExpanded recruitment locations to include numerous sites across the United States and internationally, and added related topics such as Non-alcoholic fatty liver disease and MedlinePlus Genetics. The HHS Vulnerability Disclosure item was removed.SummaryDifference2%

- Check8 days agoChange DetectedDeleted related topics: Non-alcoholic fatty liver disease and MedlinePlus Genetics from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check15 days agoChange Detected- Added related topics: Non-alcoholic fatty liver disease and MedlinePlus Genetics.SummaryDifference0.0%

- Check22 days agoChange DetectedAdded Revision: v3.3.2 under additions. Removed 'Non-alcoholic fatty liver disease', 'MedlinePlus Genetics' related topic, and Revision: v3.3.1 from deletions.SummaryDifference0.1%

- Check29 days agoChange DetectedAdded 'Non-alcoholic fatty liver disease' and related topics (MedlinePlus Genetics) to the study page, and kept the note that publications are automatically pulled from PubMed. The older PubMed-related note was removed and the revision tag updated from v3.2.0 to v3.3.1.SummaryDifference0.6%

- Check37 days agoChange DetectedThe government funding status notice and related topics (Non-alcoholic fatty liver disease and MedlinePlus Genetics) were removed from the page; core study details and navigation remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Resmetirom in NASH and Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.